Cover image of the article: Monitoring of Cyclosporine A Blood Levels in Clinical Settings

Image Credit:Nephro-Urol Mon

Monitoring of Cyclosporine A Blood Levels in Clinical Settings

Authors

Mariusz Niemczyk1,*
How to Cite:Niemczyk M. Monitoring of Cyclosporine A Blood Levels in Clinical Settings. Nephro-Urol Mon. 2012;4(2):493-494. doi: https://doi.org/10.5812/numonthly.2701

Dear Editor,
I would like to comment on the paper by Beiraghdar et al. (1). C2 is regarded as a better indicator of cyclosporine A (CsA) exposure compared to C0 (2), this is also the case in pediatric patients (3). However, in clinical settings, C0 monitoring seems to be more reliable. It is connected to the fact that, CsA blood concentration is quite stable for between 10 and 12 hours after administration, and the collection of blood during that time allows valuable clinical results to be obtained. On the other hand, the peak concentration is obtained 2 hours after administration only in a limited group of patients, so called “good absorbers.” In delayed absorbers, C2 is not fully reliable(4). Limitations of C2 monitoring have also been proven in children (5). Additionally, monitoring CsA therapy with concomitant C0 and C2 observation is more expensive and connected to double stress and blood loss. Therefore, I would support the usage of C0 as the standard method of CsA therapy observation.
Beiraghdar et al. have found several correlations between CsA blood levels and clinical parameters. A negative correlation between CsA levels and serum creatinine, however, seems surprising. I would have expected completely the opposite relationship due to the well known nephrotoxic properties of CsA. Other correlations reported by the authors also seem difficult to explain. Unfortunately, the authors did not even try to account for their results and show which elements were causes, and which were effects. Many factors may be expected to impact on the pharmacokinetics of CsA. Therefore, they may only be correlated to C0 or C2 if the study group received the same dose of CsA per kilogram of body mass. As I understand, in the reported population, CsA doses were adjusted according to CsA blood levels, and varied in different patients. Therefore, C0 and C2 should not correlate with clinical parameters, as they depend mainly on CsA dosing. To obtain clinically relevant conclusions, clinical parameters should be correlated to CsA doses. Otherwise, the results would seem to have low significance for clinical practice. Finally, is it possible that these parameters will become important in clinical decision making? I do not think so. In my opinion, what will remain of key value is C0 and clinical experience.

Footnotes

  • Please cite this paper asNiemczyk M. Monitoring of Cyclosporine A Blood levels in Clinical Settings. Nephro-Urol Mon.2012;4(2): 493-4. DoI: 10.5812/numonthly.2701

  • Financial DisclosureI have no conflict of interest to declared.

References

Copyright

Copyright © 2012, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Similar Articles

15
Dec
2012
Monitoring Cyclosporine Absorption: A Step Beyond Therapeutic Drug Monitoring

Monitoring Cyclosporine Absorption: A Step Beyond Therapeutic Drug Monitoring

Po-Chang Lee

Lee P. Monitoring Cyclosporine Absorption: A Step Beyond Therapeutic Drug Monitoring. Nephro-Urol Mon. 2012;5(1):712-713. doi: https://doi.org/10.5812/numonthly.7463

11
Mar
2017
A Systematic Review about an Advance in Cyclosporine Monitoring in Kidney Transplant Recipients

A Systematic Review about an Advance in Cyclosporine Monitoring in Kidney Transplant Recipients

Behzad Einollahi,
Mojtaba Teimoori

Einollahi B, Teimoori M. A Systematic Review about an Advance in Cyclosporine Monitoring in Kidney Transplant Recipients. Nephro-Urol Mon. 2017;9(4):e24989. doi: https://doi.org/10.5812/numonthly.24989

31
Dec
2019
Evaluation of Cyclosporine Pharmacokinetic, Monitoring, and Dosing Parameters for GVHD Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients

Evaluation of Cyclosporine Pharmacokinetic, Monitoring, and Dosing Parameters for GVHD Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients

Ali Tafazoli,
Simin Dadashzadeh,
Mahshid Mehdizadeh,
Sayeh Parkhideh,
Maria Tavakoli-Ardakani

Tafazoli A, Dadashzadeh S, Mehdizadeh M, Parkhideh S, Tavakoli-Ardakani M. Evaluation of Cyclosporine Pharmacokinetic, Monitoring, and Dosing Parameters for GVHD Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients. Iran J Pharm Res. 2019;18(Suppl1):e124682. doi: https://doi.org/10.22037/ijpr.2020.112111.13539

31
Jan
2016
A 16 Month Survey of Cyclosporine Utilization Evaluation in Allogeneic Hematopoietic Stem Cell Transplant Recipients

A 16 Month Survey of Cyclosporine Utilization Evaluation in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Maria Tavakoli Ardakani,
Ali Tafazoli,
Mahshid Mehdizadeh,
Abbas Hajifathali,
Simin Dadashzadeh

Tavakoli Ardakani M, Tafazoli A, Mehdizadeh M, Hajifathali A, Dadashzadeh S. A 16 Month Survey of Cyclosporine Utilization Evaluation in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Iran J Pharm Res. 2016;15(1):e125129. doi: https://doi.org/10.22037/ijpr.2016.1788

1
Mar
2012
Change of Cyclosporine Absorption over the Time After Kidney Transplantation

Change of Cyclosporine Absorption over the Time After Kidney Transplantation

Behzad Einollahi,
Mojtaba Teimoori,
Zohreh Rostami

Einollahi B, Teimoori M, Rostami Z. Change of Cyclosporine Absorption over the Time After Kidney Transplantation. Nephro-Urol Mon. 2012;4(2):470-474. doi: https://doi.org/10.5812/numonthly.2437

More by these authors

Mariusz NiemczykPubMedScholar
Share
Cited by
Metrics
Indexed in